Master in Vaccinology and Drug Development

Master in Vaccinology and Drug Development This program demands excellence in every aspect, from the worldwide expertise of the teaching staff

The Socioeconomic Value of Adult Immunization Programs 💡💉A new cost-benefit analysis published in Human Vaccines & Immun...
27/02/2026

The Socioeconomic Value of Adult Immunization Programs 💡💉

A new cost-benefit analysis published in Human Vaccines & Immunotherapeutics highlights the substantial socioeconomic returns of adult vaccination programs across diverse countries. 📈💼

As global populations age, decision-makers face key questions:
👉 Should adult immunization be prioritized?
👉 How do we measure its broader value beyond direct clinical outcomes?

This modeling study found that:
🔹 Vaccination programs for influenza, pneumococcal disease, herpes zoster, and RSV consistently generate positive benefit–cost ratios across ten countries.
🔹 Estimated returns often exceeded 5–19 times the investment, even after considering non-monetary benefits.
🔹 Programs with high mortality impacts (e.g., influenza and pneumococcal) yielded the highest returns.

📌 Why this matters for vaccinology:
• Adult immunization isn’t only a health intervention — it’s an economic and societal investment.
• As populations age globally, proactive immunization can protect healthcare systems and improve quality of life for older adults.
• Evidence like this strengthens the argument for expanding vaccination strategies beyond childhood schedules.

Vaccination across the life course isn’t just good science — it’s cost-effective public health policy. 🌍💪📊

Read more: https://www.tandfonline.com/doi/full/10.1080/21645515.2025.2602976

Immunization Across the Life Course: A Strategic Framework for Public Health 🌍💉Vaccination isn’t just for childhood — it...
26/02/2026

Immunization Across the Life Course: A Strategic Framework for Public Health 🌍💉

Vaccination isn’t just for childhood — it’s a lifelong public health investment. The Pan American Health Organization (PAHO-WHO ) Life Course Approach (LCA) highlights how strategic vaccination across all ages can prevent disease, reduce immunity gaps, and maximize health outcomes throughout life.

The LCA emphasizes that:
🔹 Our immune system changes over time — immunity wanes and susceptibility shifts with age.
🔹 Vaccines should be delivered when they offer the greatest benefit — from infancy to older adulthood.
🔹 Integrating immunization with other age-appropriate health services strengthens overall health trajectories.

Examples of life course immunization include:
🧒 Early childhood vaccines scheduled at critical developmental windows
🤰 Maternal vaccines that protect both mothers and infants
👵 Adult and older adult boosters that counteract immunosenescence

This approach not only closes immunity gaps at each life stage, but also helps reduce health inequities across populations and generations.

For vaccinology professionals, the life course perspective:
✔️ Reinforces the importance of tailored vaccination strategies
✔️ Encourages holistic integration with primary health care
✔️ Supports sustainable and equitable immunization programs

Vaccination isn’t just a moment in childhood — it’s a lifelong commitment to health. 🌟💪

🌐 ifgh.org

Measles Resurgence: A Global Vaccinology Challenge 🌍🦠After decades of progress toward elimination, measles is re-emergin...
25/02/2026

Measles Resurgence: A Global Vaccinology Challenge 🌍🦠

After decades of progress toward elimination, measles is re-emerging in multiple regions worldwide. This is not a vaccine failure — it is a systems failure ⚠️.

Measles remains one of the most contagious human viral diseases, with an R₀ of 12–18 🔬. Even small declines in two-dose vaccination coverage can rapidly lead to outbreaks when herd immunity thresholds (~95%) are not sustained 📉🧒.

Key drivers of resurgence include:
🔹 Declining routine immunization coverage
🔹 Vaccine hesitancy and misinformation 📲
🔹 Post-pandemic immunity gaps in children
🔹 Increased global mobility and cross-border transmission ✈️

The measles vaccine, delivered through the MMR platform, is a live attenuated vaccine with ~97% effectiveness after two doses 💉🧬. When coverage is high, outbreaks are preventable.

For vaccinology and drug development professionals, measles resurgence reinforces critical lessons:

✔️ The fragility of elimination status
✔️ The importance of sustained surveillance and catch-up strategies 🔎
✔️ The need for evidence-based vaccine confidence initiatives
✔️ The role of equity in global immunization systems 🌐

Measles is a reminder that maintaining protection requires continuous investment in science, systems, and trust 🧠📊.

🌐 ifgh.org

20/02/2026

📊 New research published in JAMA Pediatrics highlights the impact of vaccine policy on childhood immunization rates.

The study shows that eliminating nonmedical vaccine exemptions (such as personal or philosophical exemptions) is associated with higher vaccination coverage among kindergarten-aged children. States that fully removed these exemptions experienced meaningful increases in coverage for key vaccines, including MMR, DTaP, hepatitis B, and polio.

🔍 Key findings:
States that eliminated all nonmedical exemptions saw higher vaccination rates compared with states that made no policy changes.

Increases in medical exemptions were minimal, suggesting limited substitution.
Partial policy changes had smaller and less sustained effects.

🛡️ Why it matters
As childhood vaccination rates decline in several regions, evidence-based policy decisions play a critical role in preventing outbreaks of vaccine-preventable diseases and strengthening community

https://jamanetwork.com/journals/jamapediatrics/fullarticle/2840422?guestAccessKey=9a0659c9-0694-4495-bc95-3a40ada2b66a&utm_source=linkedin_company&utm_medium=social_jamapeds&utm_term=19181827018&utm_campaign=article_alert&linkId=894623655

📲 Be part of our global community and stay up to date with the latest in vaccinology and drug development!Follow us and ...
18/02/2026

📲 Be part of our global community and stay up to date with the latest in vaccinology and drug development!

Follow us and connect with experts, students, and professionals around the world:
🔹 Instagram: https://www.instagram.com/master.in.vaccinology

🔹 LinkedIn: https://www.linkedin.com/company/master-in-vaccinology-and-drug-development

🔹 X (Twitter): https://x.com/InVaccinology

🔹 Facebook: https://www.facebook.com/vaccinology.drug.development

🌐 Learn more at www.ifgh.org

Women in Science Day | February 11 👩‍🔬✨Today, we celebrate the women whose curiosity, leadership, and dedication drive ...
11/02/2026

Women in Science Day | February 11 👩‍🔬✨

Today, we celebrate the women whose curiosity, leadership, and dedication drive scientific discovery forward—especially in vaccinology and drug development.

From laboratory research to global health policy, women scientists play a vital role in advancing innovation, equity, and evidence-based solutions that protect lives worldwide.

At the Master in Vaccinology and Drug Development, we recognize and support the impact of women shaping the future of immunization and public health.

ifgh.org

06/02/2026

🌍💉 Vaccination is a lifelong investment in health

According to the World Health Organization, unlocking the full potential of immunization requires a life-course approach—protecting people not only in childhood, but throughout adolescence, adulthood, and older age.

As populations age, adult immunization becomes essential to support healthy aging, reduce preventable disease, and strengthen health systems worldwide.

📊 Expanding vaccination across all ages delivers powerful health, social, and economic benefits, reinforcing resilience at both individual and community levels.

🔗 ifgh.org

🧬 50 Years of Immunization. 154 Million Lives Saved 💉A WHO-led study shows that global immunization efforts have saved a...
03/02/2026

🧬 50 Years of Immunization. 154 Million Lives Saved 💉

A WHO-led study shows that global immunization efforts have saved at least 154 million lives over the past 50 years— the equivalent of 6 lives saved every minute, every year.

👶 More than 101 million of these lives were infants under one year of age, highlighting the critical role vaccines play from the very start of life.

💪 Measles vaccination alone accounts for nearly 60% of all lives saved, demonstrating the extraordinary impact of sustained vaccination programs.

This milestone reinforces why vaccinology and drug development remain central to global public health — and why continued education, research, and innovation in this field are essential to protect future generations.

🔗 Read more: https://www.who.int/news/item/24-04-2024-global-immunization-efforts-have-saved-at-least-154-million-lives-over-the-past-50-years

🌍 World Neglected Tropical Diseases Day | Leaving No One BehindNeglected tropical diseases (NTDs) affect more than 1 bil...
30/01/2026

🌍 World Neglected Tropical Diseases Day | Leaving No One Behind

Neglected tropical diseases (NTDs) affect more than 1 billion people worldwide, disproportionately impacting the most vulnerable and underserved communities.

From vaccines and medicines to diagnostics and implementation strategies, science and innovation play a critical role in preventing, controlling, and ultimately eliminating NTDs. Progress is possible — but only through sustained investment, research, and global collaboration.

On World Neglected Tropical Diseases Day, we reaffirm the importance of advancing vaccinology and drug development to close equity gaps and ensure that no disease — and no population — is neglected.

ifgh.org

For years, the Master in Vaccinology and Drug Development has helped shape the global vaccinology workforce.Through rigo...
29/01/2026

For years, the Master in Vaccinology and Drug Development has helped shape the global vaccinology workforce.

Through rigorous academic standards, international collaboration, and real-world impact, the program has trained professionals who now contribute to immunization programs, vaccine development, and public health decision-making worldwide.

Its sustained excellence reflects a long-standing commitment to evidence-based science and global health leadership.

🔗 Learn more about us:
https://ifgh.org/educational-programs/master-in-vaccinology-and-drug-development/

Remembering Bill Foege — a true public health heroWilliam “Bill” Foege, MD, legendary epidemiologist credited with devel...
27/01/2026

Remembering Bill Foege — a true public health hero

William “Bill” Foege, MD, legendary epidemiologist credited with developing the ring vaccination strategy that helped eradicate smallpox, has died at 89. He led global health efforts at the CDC, WHO, UNICEF and co-founded the Task Force for Global Health. His work expanded childhood immunizations worldwide and shaped modern public health practice.

🌍 From smallpox eradication to fighting HIV and improving vaccine access, Foege’s legacy of science in the service of humanity will continue to inspire public health leaders everywhere.

🕊️ Thank you, Dr. Foege.

📢 New NEJM Evidence: High-Dose Flu Vaccine & Hospitalizations in Older AdultsA recent study published in The New England...
27/01/2026

📢 New NEJM Evidence: High-Dose Flu Vaccine & Hospitalizations in Older Adults

A recent study published in The New England Journal of Medicine evaluated whether a high-dose inactivated influenza vaccine could better prevent hospitalizations from influenza or pneumonia compared to the standard-dose vaccine among adults 65–79 years old.

🔬 Key results: In this large, registry-based, randomized trial in Spain, people aged 65–79 who received the high-dose vaccine had fewer hospitalizations for influenza or pneumonia than those who received the standard dose.

📊 Although hospitalizations were rare overall, the relative effectiveness against combined influenza/pneumonia hospital admissions was notable—and serious adverse events were similarly low in both groups.

💡 Why it matters:
• Influenza remains a major cause of severe illness in older adults.
• Optimizing vaccine strategies—like using high-dose formulations—could help reduce severe outcomes and lighten the burden on health systems during flu seasons.
• These findings support evidence-based decisions on influenza immunization in older populations.

🔗 Read the full article 👉 https://www.nejm.org/doi/full/10.1056/NEJMoa2509834

Indirizzo

Via Val Di Montone
Siena

Sito Web

Notifiche

Lasciando la tua email puoi essere il primo a sapere quando Master in Vaccinology and Drug Development pubblica notizie e promozioni. Il tuo indirizzo email non verrà utilizzato per nessun altro scopo e potrai annullare l'iscrizione in qualsiasi momento.

Contatta Lo Studio

Invia un messaggio a Master in Vaccinology and Drug Development:

Scelte rapide

Condividi

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Digitare

Our Vision & Goal

Through our Master Program in Vaccinology and Drug Development, young doctors in medical and biological sciences develop the valuable scientific and practical knowhow they need to join the new generation of public health leaders in developing countries.

With this program the degreed students will carry on the capacity building in vaccinology and drugs development, having the knowledge to ascend with their careers in the academia, public health and research and development in public and private institutes.